A range of 17 ternary formulations of itraconazole (ITZ), HPMCP and Soluplus have been 10 manufactured using spray drying. These amorphous solid dispersions (ASDs) were very stable 11 against crystallisation and ITZ was found to be amorphous in all formulations after one year at 12 40 o C / 75% RH. A number of solid state analytical techniques including PXRD, DSC, small angle 13 X-ray scattering, FTIR and solid state NMR were used to characterise the physicochemical 14 properties of the ASDs following processing and storage and to assess any interactions between 15 components. Microtrac laser scattering analysis revealed a relationship between polymer levels and 16 particle size distribution (PSD). Dissolution studies indicated that higher Soluplus content in the 17 formulation resulted in higher concentrations of ITZ in acidic media. 18
INTRODUCTION 21
Despite the disparity between the significant research efforts in the past four decades and the 22 number of successfully introduced systems into the market, the preparation of amorphous solid 23 dispersions (ASDs) still holds a key position among the various formulation approaches intended to 24 improve the dissolution rate of BCS II compounds (Guns et al., 2011) . With higher Gibbs free 25 energy than their crystalline counterparts, amorphous systems possess greater apparent aqueous 26 solubility but are thermodynamically unstable, exhibiting a tendency towards spontaneous 27 crystallisation. To enhance the physical stability of pure amorphous active pharmaceutical 28 ingredient (API) a carrier, often an amorphous polymer, can be used to provide practical physical 29 stability to the amorphous systems (Vasconcelos et al., 2007) . The inclusion of an additional 30 polymer, however, selected based on its physiochemical properties, enables the design of more 31 sophisticated delivery strategies with the amorphous drug in solid dispersion exhibiting a reduced 32 particle size and lower thermodynamic barrier to dissolution (Verma and Rudraraju, 2014) . 33
Several formulation approaches and manufacturing techniques to prepare ASDs containing 34 poorly water soluble APIs have been introduced, for example spray drying (SD), hot melt extrusion 35 (HME) and freeze drying (FD) (Douglas et al., 2015 ) (Kumar et al., 2014 ) (Cerdeira et al., 2013) . 36 Among these, spray drying is being more and more utilised to develop solid molecular dispersions 37 of poorly soluble drugs (Hengsawas Surasarang et al., 2016) (Sawicki et al., 2016) resulting in 38 enhanced solubility and the development of sustained and targeted drug delivery systems. 39
Physicochemically, itraconazole (ITZ) can be categorised as a weak base, BCS class II 40 compound with very poor water solubility of 1 ng/mL at neutral pH. The first oral dosage form of 41 itraconazole was manufactured using a solid solution method in which the solvent based drug-42 polymer mixture was sprayed onto an inert sugar sphere in a closed Wurster process (Peeters et al., 43 2002) . However, where most ASDs in the literature have been binary systems, comprising of drug 44 and excipient polymer, reports have suggested that ternary ASD systems can have a stability 45 advantage over binary (Six et al., 2004) . 46
The aim of this project was to generate an optimised formulation comprising amorphous 47 itraconazole and two excipient polymers in which the itraconazole was stable in the amorphous 48 form over an extended period and which exhibited the capability to produce and maintain a 49 supersaturation of itraconazole in acidic media. 50
MATERIALS AND METHODS 51

Materials 52
Itraconazole (>99%) was purchased from Xi'an Lyphar Biotech Ltd. Accurate analytical standard 53 of itraconazole (99.8%) for HPLC calibration was purchased from Sigma Aldrich. Polymers 54
Soluplus and HPMCP HP-55 (HPMCP) were donated by BASF and Shin Etsu respectively. 55
Solvents and chemicals were purchased from Sigma-Aldrich and were of HPLC and reagent grade. 56
Pre-formulation polymer and solvent selection test 57
In a typical experiment dichloromethane-methanol (1:1 v/v, 5 mL) was added to itraconazole 58 (30 mg), Soluplus (30 mg) and HPMCP (40 mg) followed by vortex mixing (5 min) and visual 59 inspection. 60
Design of Experiments (DoE) 61
Design-Expert 9.0.6 software (Stat-Ease, Minneapolis) was utilised to generate a variety of 17 62 optimised formulations containing drug loads of 10 -30% ( Figure 2 and Table 1 ). DoE has been 63 employed to provide a methodical way of choosing the drug-polymer ratios. 64
Spray drying 65
A Büchi B-290 mini spray dryer was set up with a B-295 inert loop to enable the use of organic 66 solvents and was connected to a condenser maintained at -20 °C and a high efficiency cyclone. A 67 0.7 mm 2-fluid pneumatic nozzle was fitted and the API -polymer solution was sprayed under a 68 stream of nitrogen. Atomising nitrogen flowrate was ~473 L/h and the aspirator for the drying 69 nitrogen was set to 100% (35 m 3 /h). The solution (0.5% w/v) of ITZ, Soluplus and HPMCP in 70 dichloromethane -methanol (500 mL, 1:1 v/v) was pumped at 4 mL/min. Samples were removed for analysis at day 0, one month, three months and one year by PXRD. 80
Other techniques mentioned directly below ascertained the stability of the powders after one year at 81 these conditions. 82
Powder X-ray diffraction (PXRD) and Small-angle X-ray scattering (SAXS) 83
A PANalytical Empyrean X-ray diffractometer attached to a computer running High Score Plus 84 was used to collect and process X-ray data. Diffraction patterns were collected in-situ, by spinning 85 powders on zero background discs within the X-ray beam. Molecular interactions between ITZ and the polymers were characterised using an FT-IR 115 spectrometer equipped with a universal attenuated total reflection (ATR) accessory (PerkinElmer 116 Spectrum 100). A small amount of each sample was placed in the ATR cell, and pressure was 117 applied with a pressure arm. Scans were collected in the range of 4,000-650 cm −1 using the 118 Spectrum software package (PerkinElmer, MA, USA). 119
Scanning electron microscopy (SEM) 120
Drug polymer formulations were attached to double sided carbon tape and sputter coated with a 121 thin layer of gold followed by imaging using a Joel CarryScope JCM-5700 scanning electron 122 microscope. Micrographs were recorded at 500, 2000 and 5000 times magnification, using a beam 123 acceleration voltage of 5 kV, a spot size of 40 and a working distance of 12. 124
Supersaturated in vitro dissolution studies 125
The dissolution studies were carried out under non-sink conditions in glass bottles (100 mL) 126 equipped with magnetic stirring bars (30 mm) rotating at 100 rpm. Glass vessels were charged with 127 dissolution media (0.1 N HCl, 75 mL) at 37 ± 0.5 o C. A quantity of formulation or drug equivalent 128 to 37.5 ± 1 mg of ITZ (375 µg/mL, approximately 100 times the 0.1N equilibrium concentration 129 solubility of 4 µg/mL), was weighed into a glass vial. The powder was pre-wetted with 2 mL of pre-130 heated HCl media using a Pasteur pipette and quantitatively washed into the dissolution media. 131
During testing, samples (1.0 mL) were removed by syringe at 1, 2, 3, 4, 5, 6 and 24 h (without 132 replacement) and immediately filtered (0.45 µm PTFE syringe filters) into HPLC vials already 133 containing an equal volume of mobile phase (to minimise adsorption or crystallisation). 134
Immediately after the second sample (2h), tribasic sodium phosphate (0.2M, 25 ± 1 mL) was added 135
to give a neutral pH of 6.8 ± 0.1 using a calibrated pH meter, in accordance with USP guidelines for 136 extended release dosage forms (Method A). 137
High performance liquid chromatography (HPLC) 138
Dissolution samples were analysed using an Agilent (Agilent, Little Island, Cork) 1260 Infinity 139 II high performance liquid chromatography system, comprising of quaternary pump G1311B, diode 140 array detector G1315D set at wavelength 263 nm, autosampler G1329B and thermostated column 141 compartment G1316A set at 25.0 o C. The system was operated under isocratic flow at 1 mL/min 142 using a mobile phase of acetonitrile:water:diethanolamine (69.95/30/0.05) equipped with a 143
Phenomenex Luna 5 µm C18(2) 100 Å 150 mm x 4.6 mm (Phenomenex, Macclesfield, Cheshire) 144 RP-HPLC column. Samples collected from the dissolution assay were injected in volumes of 20 µL. 145
Data were collected and analysed using Aglilent ChemStation software version C.01.07. Standards 146 of ITZ (99.8% purity) were prepared in methanol from a stock solution of 1 mg/mL to quantify the 147 levels of drug in the samples. 148
Particle size distribution (PSD) 149
A Microtrac S3500 series particle size analyser with tri-laser technology (Microtrac Inc., 150
Montgomeryville, PA) was used to determine the particle size distribution of the samples. Dry 151 measurements were carried out using air as the medium to convey the sample to the measuring cell. 152
RESULTS AND DISCUSSION 153
Polymer selection 154
The system was designed to contain two polymers with differing solubilities in aqueous media, 155 similar to the system previously reported by Six and co-workers (Six et al., 2004) . The dissolution 156 of itraconazole is typically carried out in acidic media so one enteric and one non-enteric polymer 157 were selected. Based on miniaturised solvent casting studies previously carried out in this group, 158
Soluplus and HPMCP were selected (Davis et al., 2015) . Soluplus is amphiphilic in nature and 159 aqueous-soluble while HPMCP is insoluble in acidic aqueous conditions. Furthermore, Soluplus 160 would be expected to exhibit a greater wettability and hydrophilicity than HPMCP (Zhong et al., 161 2016). The functional group chemistry of Soluplus includes H-bond acceptors caprolactam and 162 acetate whilst the PEGylated region improves aqueous solubility (Figure 1 ). HPMCP contains 163 phthalate which contributes to lowering the overall aqueous solubility, but imparts hydrogen-bond 164 donation capability. Ternary formulation design is displayed in Figure 2 . 165 This work involved spray drying and was run concurrently with an hot melt extrusion project in 166 our group also studying ternary ITZ-Soluplus-HPMCP blends, so it was important that the selected 167 polymers were suitable for both spray drying and hot melt extrusion. One of the advantages of spray 168 drying is the ease with which excipients with differing properties can be incorporated, provided that 169 a mutually appropriate solvent can be found. Hot melt extrusion, however, relies on excipients 170 having suitable thermoplastic properties. Soluplus is suitable for processing by both hot melt 171 extrusion and solvent evaporation (spray drying) methods while HPMCP, as a cellulosic polymer 172 with a high Tg, can be difficult to extrude without the use of plasticisers (Karandikar et al., 2015) . 173 HPMCP also has a proven record as a suitable polymer for the formulation of ITZ (Parikh et al., 174 2015) . Lozanoc ® (Mayne Pharma, Australia) has recently come to market in Australia and the EU 175 and is a 40% dispersion of ITZ on 60% HPMCP HP-50. In our studies of these systems, we have 176 found that the inclusion of Soluplus with HPMCP has led to ease of processing by hot melt 177 extrusion and contributes to higher drug concentrations in acidic media. 178
Spray Drying 179
A solubility screening step was introduced prior to spray drying to ensure that the three 180 components were in solution to aid production of a homogenous product. After a range of 181 permutations, dichloromethane-methanol (1:1) was selected as the solvent as it was capable of 182 completely dissolving all three components at the required loading. The spray dried product was a 183 white, fluffy powder which, following inspection using SEM, was shown to be comprised of 184 particles with a collapsed or dimpled shape. The development of particles of this nature with an 185 uneven surface has been associated with the spray drying of solutions with a Peclet number greater 186 than 1 which causes regions of high viscosity to develop on the surface of the particles during 187 drying and which is typical of solutions containing polymers (Vehring, 2008 )(Bittner and Kissel, 188 1999). The resultant powders from each run were also analysed by Microtrac particle size analysis. 189
The 
DSC 211
Through the use of the Perkin Elmer DSC8500 it was possible to explore the use of much faster 212 heating rates than are used during standard DSC. In increasing heating rate the sensitivity of the 213 DSC is also increased and thus smaller transitional changes can be detected beyond the threshold of 214 instrumental noise (Craig and Reading, 2006 ). This analysis method was therefore utilised as one 215 which might give better sensitivity to any crystallinity contained in the formulations. All of the 216 samples from the stability study were tested i.e. from the desiccator and from the Amebis ® system 217 at 40 o C / 75% RH and even using this increased sensitivity analysis method the absence of any 218 melt exotherm around the melting point of the API (168.7 ± 0.3 °C measured using a heating rate of 219 100 °C/min) was confirmed (Figure 4) . 220
The difficulty in measuring the glass transition event in celluloses is well known (McPhillips et  221 al., 1999) so having the capability to probe the thermal glass transition region using increased 222 heating rates was advantageous. A disadvantage associated with increasing the heating rate in DSC 223 is the decreased resolution of thermal events. Two peaks which may be fully resolved at a slower 224 heating rate can merge together when heated more quickly. For this reason 100 °C / min was 225 determined to be the optimum heating rate for the detection of crystalline material around the 226 melting point of the API, however to better detect the weak Tg of HPMCP 200 °C / min was used. 227
At this heating rate the measured Tg of ITZ, Soluplus and HPMCP is 59.0 ± 0.9, 82.1 ± 2.2 and 228 147.6 ± 1.5 o C (all n = 3) respectively. Van den Mooter and co-workers claimed that the anti-229 plasticising effect of the polymer, rather than intermolecular interactions, was the only relevant 230 factor (Van den Mooter et al., 2001) contributing to system stability. HPMCP has a greater 231 stabilising influence on ITZ than Soluplus either through its propensity to hydrogen bond with ITZ 232 or due its higher Tg. 233
Analysis of the glass transition region of the DSC thermograms indicated that two glass 234 transitions were present in the samples (Table 1) . A single glass transition area is often desired in an 235 ASD as it indicates that the system is completely homogenous and that the components have been 236 well mixed during processing (Huang and Dai, 2014) . In practice, it was observed that each 237 formulation had two glass transitions, one just below or around the glass transition value of 238
Soluplus and one just below that of HPMCP, corresponding to HPMCP-rich and Soluplus-rich 239 amorphous drug phases. None of the measured Tgs corresponded to the value of pure itraconazole 240 so it could be concluded that rather than the drug separating out from the polymer, that the drug had 241 remained associated with the two polymers, but that the polymers themselves had either partially or 242 fully dissociated from each other. The interactions between drug and polymers in a ternary system 243 are extremely complex. Due to the size of the polymers and the large number and variety of 244 functional groups a huge number of intermolecular association permutations are possible. Drug-245 drug, drug-polymer 1, drug-polymer 2, polymer 1-polymer-1, polymer 1-polymer 2, polymer 2-246 polymer 2 interactions are all possible, even before the complexities of water vapour uptake are 247 considered. 248 3 3 2 2 1 1 3 3 3 2 2 2 1 1 1
The Couchman-Karasz equation for ternary systems (Equation 1) can be used to predict the 250 value of the glass transition temperature(s) of such systems (Levine, 2002 Due to the complexity of the ternary systems, the assumption of ideal mixing incorporated into 257 the Couchman-Karasz equation may not be applicable; nevertheless, the values produced from the 258 equation generally fell near to the halfway point between the two present values. The forces behind 259 such a separation are unclear, but may be due to polarity and conformational flexibility issues. In 260 any case, the stability against crystallisation of the ternary systems was excellent and the solubility 261 was greatly increased compared to the crystalline drug and these outcomes were considered to be 262 the most important, although a single homogenous formulation would be preferred. 263
DOE RESULTS 264
The factors measured were the weight percents (% w/w) of formulation ingredients; factor A: 265 ITZ, factor B: Soluplus, and factor C: HPMCP and their percent amounts sum to 100%. The limits 266 for the percent amounts of ITZ 10% ≤ A ≤ 30% and Soluplus and HPMCP 30% ≤ B/C ≤ 60%. Two 267 responses were recorded, namely the value of the two measured Tgs (Tg1 and Tg2 in Table 1), and  268 analysis of data was carried out using two separate ANOVA; one for each response). A graphical 269 representation of the results for the two models is shown in Figure 2 . Values of "Prob > F" less than 0.0500 indicate model terms are significant. Model 1 exhibited a 277 model F-value of 3.1 and a "Prob > F" of 0.0411 while the similar values for model 2 were 26.78 278 and 0.0001, implying that both models are significant. There is only a 4.11% or 0.01% (model 1 and 279 2 respectively) chance that F-values this large could occur due to noise. In both cases A, B and C 280 terms are significant model terms. 281
From Figure 2a is it observed that Tg1 increases with increasing Soluplus content. This 282 observation is in agreement with the characterisation of these formulations as containing a 283
Soluplus-rich and an HPMCP-rich amorphous phase. Therefore as the amount of Soluplus in the 284 formulation increases, the ratio of Soluplus to ITZ in the Soluplus-rich phase increases, thus causing 285 an increased overall Tg due to the higher Tg of the polymer in comparison to the API. From Figure  286 2b it is observed that as HPMCP content increases, Tg2 is increased. There is, however, a difference 287 in the gradient of the contour lines between the two models. For model 1 ITZ and HPMCP are 288 given similar weighting in the calculation of Tg1, with the contour lines orthogonal to the Soluplus 289 axis. Conversely for model 2, the contour lines are shifted toward Soluplus, suggesting a change in 290 the contribution of Soluplus to Tg2 depending on HPMCP content and a possible limit to the 291 miscibility of Soluplus in the ITZ-HPMCP system. 292
FTIR and ssNMR 293
The FTIR spectra for the formulations prepared in this study and the individual components are 294 presented in Figure 5 . At 898 cm -1 a peak was observed in the crystalline sample of ITZ only. The 295 peak was not present in the amorphous sample of ITZ (prepared by melt quench), in any of the 296 formulations or the polymers. 898 cm -1 is most likely due to an aromatic C-H out-of-plane bending 297 vibration. ATR-FTIR represents a rapid test method for qualitatively determining the presence or 298 absence of crystalline ITZ with minimal sample preparation time. 299
The impact of hydrogen-bonding in amorphous dispersion stability has been well documented 300 (Vasanthavada et al., 2005) . ITZ cannot self-associate through H-bonding, as it contains only donor 301 functional groups, however it can H-bond to HPMCP and may form other associations with 302
Soluplus. Soluplus cannot self-associate as it contains only acceptors, but can H-bond with 303 HPMCP. HPMCP can associate with itself, the drug and Soluplus as it contains both acceptors and 304 donors. The phthalate functional group is able to associate favourably with the ITZ aromatic rings 305 through π-π interactions. Conformational flexibility of the components will be limited by rotational 306 degrees of freedom around individual bonds reducing the number of possible interactions. For 307 instance, HPMCP will be limited in flexibility due to the preferred orientation of the glucopyranose 308 rings. 309
Solid state NMR spectra were recorded of ASD 16 (containing 30% drug load, 40% Soluplus 310 and 30% HPMCP) after one year of storage in a desiccator (Figure 6 ). The data compared well with 311 that previously reported (Van Eerdenbrugh et al., 2009) (Song et al., 2015) . Broadening of the peaks 312 in ASD 16 relative to crystalline ITZ indicated that the drug was in the amorphous form. ssNMR 313 also provides additional structural information confirming that the drug was also chemically intact 314 and had not oxidised or otherwise degraded. 315
Dissolution studies 316
HPLC analysis was performed rather than UV assay to ensure that absorbance was due to analyte 317 (ITZ) rather than impurities or polymer (e.g. phthalate groups). The retention time of ITZ was 318 approximately 9.3 min with consistent reproducibility and no unexplained peaks or baseline drift 319 were encountered. All analytical tests maintained system suitability limits for linearity from 0.100 320 to 100 µg/mL (r 2 ≥ 0.999) and reproducibility of replicate injections (% RSD < 0.3% Figure 7 . 329 Formulation composition and concentration values are displayed in Table 1 and Figure 8. A  330 comparison of formulation, dissolution and particle size reveals that formulations richer in Soluplus 331 generally had a lower D50 particle size distribution and a higher solubility. Formulations richer in 332 HPMCP generally had higher D50 particle size distribution and had lower solubility (Figure 9 ). The 333 reason for the larger PSD is most likely because HPMCP has a much greater effect on viscosity 334 than Soluplus or ITZ. When viscosity is higher droplet formation is more difficult so larger droplets 335 are formed (Vehring, 2008 Table  439 1). Plot fill colour indicates (a) Tg1 and (b) Tg2 value for the given formulation composition. 
462
Crystalline ITZ released 4 µg / mL after 1 h, but was below the limit of detection (100 ng / mL) post neutralisation, due 
